FILING ANALYSIS · THURSDAY, NOVEMBER 5
REGENXBIO Inc. RGNX — 8-K: Results of Operations and Financial Condition
neutral
REGENXBIO's Q3 financial results and operational highlights show progress in its gene therapy pipeline, including the expected BLA submission for RGX-202 in Q1 2027 and topline data from pivotal subretinal wet AMD studies in Q4 2026, with a cash position of $251 million as of September 30, 2026, boosted by a $100 million milestone payment from AbbVie and net proceeds from an underwritten public of
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →